Earlier today I posted two points to consider in this thread; I'll add a third point here:
Third, keep in mind that the Provenge phase-3 trial showed a median improvement of 4.5 months survival. As you probably know, the way these drugs work is that they do work for some people, and others they simply don't work for. So, some men had far greater survival than the 4.5 month median value. The trial is required to report 3-year results, where 34% of the patients on Provenge were still alive, versus 11% for the placebo. In other words, the odds of being alive 3-years later were 3-times higher for those who took Provenge.
To my point earlier that Provenge is not the "endpoint", keep your eyes out for Zibotentan, which may be the next advancement beyond Provenge. The phase-2 median survival benefit was 7 months, and the daily pill format is cheaper and more convenient to administer to patients.
Post Edited (Casey59) : 9/27/2010 2:16:34 PM (GMT-6)